Most Read Articles
Dr Margaret Shi, 18 May 2020

A blood test is shown to be feasible and safe for early detection of multiple cancers in women with no current or known history of cancer, enabling early treatment with curative intent in a subset of individuals.

Christina Lau, 12 May 2020

Patients with advanced non-small-cell lung cancer (NSCLC) who have a past medical history of pneumonitis are at increased risk of treatment-related pneumonitis (TAP) from immune checkpoint inhibitor (ICI) regimens or chemotherapy alone, an analysis of clinical trial and real-world data has shown.

13 Feb 2020
At the recent National Haematology Expert Meeting 2019, a panel of experts was convened to discuss the role of targeted therapy in the management of haematological malignancies. Highlights of their lectures are summarised below.
Dr Margaret Shi, 14 May 2020
Pembrolizumab monotherapy improves overall survival (OS) and cancer control compared with platinum-based chemotherapy in patients with untreated locally advanced or metastatic programmed death-ligand 1 (PD-L1)–positive non-small-cell lung cancer (NSCLC) regardless of STK11 or KEAP1 mutation status, according to results of the phase III KEYNOTE-042 study. 

Folic acid supplementation ups risk of sessile serrated adenomas/polyps

14 Oct 2019

There are no delayed treatment effects with folic acid supplementation, but it appears to be associated with a higher risk of sessile serrated adenomas/polyps (SSA/Ps), a study has found.

A total of 1,021 participants diagnosed with colorectal adenomas were randomized to 1 mg/d of folic acid (n=516) or placebo (n=505), with or without aspirin. The original 3-year treatment period was extended into a subsequent colonoscopy interval but was stopped prematurely on 1 October 2004.

After the initial 3-year follow-up, 66 participants who extended treatment underwent a second colonoscopic surveillance interval with additional post-treatment follow-up. Information about a subsequent surveillance colonoscopy occurring before completion of follow-up on 31 May 2012 was provided by 490 participants, including 325 who extended treatment.

Conventional adenoma, SSA/P or colorectal cancer was the study endpoint. Risk ratios (RR) and 95 percent confidence intervals (CIs) were adjusted for baseline characteristics associated with availability of follow-up.

Of the participants who extended treatment, 118 (36 percent) in the placebo group and 146 (43 percent) in the folic acid group had any colorectal neoplasia during the second surveillance interval (RR, 1.21, 95 percent CI, 0.99–1.47; p=0.06).

Extended folic acid supplementation was statistically significantly associated with an increased risk of SSA/Ps during the second surveillance interval (RR, 1.94, 1.02–3.68; p=0.04).

No evidence of post-treatment effects were found for any colorectal neoplasia (RR, 1.01, 0.80–1.28; p=0.94). Additionally, there was no longer a statistically significant post-treatment effect for SSA/P (RR, 1.38, 0.59–3.19; p=0.46).

“The Aspirin/Folate Polyp Prevention Study previously found [that] folic acid increased [the] risk of advanced and multiple colorectal adenomas during a surveillance colonoscopy interval starting about 3 years after randomization,” the authors said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Dr Margaret Shi, 18 May 2020

A blood test is shown to be feasible and safe for early detection of multiple cancers in women with no current or known history of cancer, enabling early treatment with curative intent in a subset of individuals.

Christina Lau, 12 May 2020

Patients with advanced non-small-cell lung cancer (NSCLC) who have a past medical history of pneumonitis are at increased risk of treatment-related pneumonitis (TAP) from immune checkpoint inhibitor (ICI) regimens or chemotherapy alone, an analysis of clinical trial and real-world data has shown.

13 Feb 2020
At the recent National Haematology Expert Meeting 2019, a panel of experts was convened to discuss the role of targeted therapy in the management of haematological malignancies. Highlights of their lectures are summarised below.
Dr Margaret Shi, 14 May 2020
Pembrolizumab monotherapy improves overall survival (OS) and cancer control compared with platinum-based chemotherapy in patients with untreated locally advanced or metastatic programmed death-ligand 1 (PD-L1)–positive non-small-cell lung cancer (NSCLC) regardless of STK11 or KEAP1 mutation status, according to results of the phase III KEYNOTE-042 study.